Benjamin Levy, MD:We’ll start with the obvious, withEGFR-mutated lung cancer, which has been the leading edge of targeted therapies for advanced stage non—small cell lung cancer. Zofia, do you want to walk us through where we were, and where we are with current therapies forEGFR-mutated...
The role of radiotherapy (RT) in EGFR-mutated (EGFRm) stage IV NSCLC requires clarification, especially with the advent of next-generation TKIs, which are more potent and exhibit greater central nervous system activity. In particular, the feasible application of RT, including the timing, site, ...
Mutated EGFR-IN-3 -简介 Mutated EGFR-IN-3是一种EGFR(表皮生长因子受体)抑制剂,通常用于抑制恶性肿瘤细胞的生长。 性质:Mutated EGFR-IN-3是一种固体,通常为白色至淡黄色结晶固体。它在溶剂中溶解度较好。 制法:Mutated EGFR-IN-3的制备一般是通过多步有机合成的方式合成而成,具体合成路线需要具备化学合成技...
Mutated EGFR-IN-1产品规格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg发货周期:1～3天产品价格:询价本产品仅可用于科研实验,严禁用于其他非科研用途!Mutated EGFR-IN-1是突变型EGFR(L858R EGFR,Exonl9缺失活化突变和T790M抗性突变)抑制剂的中间体。注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!CAS号:1421372...
Promising data from the phase 1 trial led to initiation of the phase 2 HERTHENA-Lung01 trial of HER3-DXd in patients with EGFR-mutated NSCLC who were treated previously with EGFR TKI and platinum-based chemotherapy Study Design Patient population had advanced E...
Mutated EGFR-IN-1 (Osimertinib analog) 是突变型 EGFR抑制剂的中间体。 产品性质 英文别名(English Synonym) Mutated EGFR-IN-1 中文名称(Chinese Name) / 靶点(Target) EGFRL858R;EGFRExon 19 deletion/T790M;EGFRT790M 通路(Pathway) JAK/STAT Signaling ...
中文名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品规格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg Mutated EGFR-IN-1是突变型EGFR(L858R EGFR,Exonl9缺失活化突变和T790M抗性突变)抑制剂的中间体。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!
特别提示:包括突变型EGFR抑制剂(Mutated EGFR-IN-1)在内,本公司的所有产品仅可用于科研实验,严禁用于临床医疗及其他非科研用途! 产品名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品货
产品名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品货号:M02094 产品规格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg Mutated EGFR-IN-1是突变型EGFR(L858R EGFR,Exonl9缺失活化突变和T790M抗性突变)抑制剂的中间体。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途! CAS号:142...
Most patients with advanced non-small-cell lung cancer (NSCLC) develop resistance to first-line treatment. However, dual epidermal growth factor receptor (EGFR)doi:10.2139/ssrn.3751803Zhou, QingCheng, YingLiu, Yun-PengChen, Gong-YanCui, Jiu-Wei...